您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > R 80123
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
R 80123
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
R 80123图片
CAS NO:133718-30-6
规格:98%
分子量:459.54
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍

R80123是R79595的Z异构体,也是一个高的选则性的phosphodiesterase的抑制剂,他的作用和Revizinone(R80122)相似。
CAS:133718-30-6
分子式:C26H29N5O3
分子量:459.54
纯度:98%
存储:Store at -20°C

Background:

R 80123 is the Z-isomer of R 79595, is also a highly selective phosphodiesterase inhibitor. The fuction is similar to R 80122 (Revizinone).In vivo: The administration of Revizinone improved the haemodynamic profile with an increase in cardiac output, a decrease in systemic vascular resistance and a stable heart rate and mean arterial blood pressure. [1] With regard to reconstitution of contractility and cardiac function Revizinone (E-isomer) is 10 fold more potent than R 79595  and nearly 100 fold more potent than R 80123 (Z-isomer). [2]  Revizinone significantly increases global LV function and systolic wall thickening in ischemic areas at doses greater than or equal to 0.16 mg/kg i.v. [3]

参考文献:

[1]. Vandeplassche GM et al. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. J Cardiovasc Pharmacol. 1992 May;19(5):714-22.https://www.ncbi.nlm.nih.gov/pubmed/ 1381769                   

[2]. Schneider J et al. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):563-72.                                                                

[3]. Vandeplassche GM et al. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. J Cardiovasc Pharmacol. 1992 May;19(5):714-22.